1-(2-乙酰基苯基)哌嗪 | 439815-18-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-乙酰基苯基)哌嗪
• 英文名称: 1-(2-acetylphenyl)piperazine
• 英文别名: 1-(2-Piperazin-1-ylphenyl)ethanone
• CAS: 439815-18-6
• 化学式: C₁₂H₁₆N₂O
• mdl: MFCD19374322
• 分子量: 204.272
• InChiKey: VDHCQPUNPXUTBB-UHFFFAOYSA-N

物化性质

• 沸点：
  358.8±27.0 °C(Predicted)
• 密度：
  1.079±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-乙酰基苯基)哌嗪 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Identification of agonists and antagonists of the human melanocortin-4 receptor from piperazinebenzylamines

  摘要：

  SAR studies of a series of piperazinebenzylamines resulted in identification of potent agonists and antagonists of the human melanocortin-4 receptor. Thus, the 1,2,3,4-tetrahydroisoquinolin-1-ylacetyl compound 12e and the quinolin-3-ylcarbonyl analogue 121 possessed K(i) values of 6.3 and 4.5nM, respectively. Interestingly, 12e was a full agonist with an EC(50) value of 31 nM. and 121 was a weak partial agonist (IA = 17%) and functioned as an antagonist (IC(50) = 300 nM). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.096
• 作为产物：
  描述：

  2'-氟苯乙酮 在 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(2-乙酰基苯基)哌嗪
  参考文献：
  名称：

  Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor

  摘要：

  SAR studies of a series of piperazinebenzylamines resulted in the discovery of potent antagonists of the human melanocortin-4 receptor. Compounds 11c, 11d, and 11l, which had K-i values of 21, 14, and 15 nM, respectively, possessed low efficacy in cAMP stimulation (similar to15% of alpha-MSH maximal level) mediated by MC4R, and functioned as antagonists in inhibition of alpha-MSH-stimulated cAMP release in a dose-dependent manner (11l, IC50 = 36 nM). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.055

文献信息

• [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
  申请人：Clark D. Jerry

  公开号：US20050043309A1

  公开（公告）日：2005-02-24

  This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R 1 , and R 4 through R 7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

  这项发明涉及公式1的化合物 其中G、D、A、Z、Q、X、Y、R 1 和R 4 至R 7 的定义如规范中所述，制备这些化合物的方法以及用于制备这些化合物的中间体，以及含有这些化合物的药物组合物及其在治疗中枢神经系统疾病和其他疾病中的用途。
• [EN] LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO<br/>[FR] LIGANDS DU RECEPTEUR DE LA MELANOCORTINE ET COMPOSITIONS ET METHODES ASSOCIEES
  申请人：NEUROCRINE BIOSCIENCES INC

  公开号：WO2005040109A1

  公开（公告）日：2005-05-06

  Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): (R4)s (R 2)n N~ X1-X2 (CR1aCRlb)q 1~ N R1-lm 1 O R3 (I) including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, q, s, R1, R1a, R1b, R2, R3, R4, X1 X2 and X3 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

  化合物作为黑色素皮质激素受体配体，并在治疗基于黑色素皮质激素受体的疾病中具有用途。这些化合物具有以下结构（I）：（R4）s（R 2）n N〜X1-X2（CR1aCRlb）q 1〜N R1-lm 1 O R3（I），包括立体异构体，前药和其药用盐，其中m、n、q、s、R1、R1a、R1b、R2、R3、R4、X1、X2和X3如本文所定义。还公开了含有结构（I）化合物的药物组合物，以及与其使用相关的方法。
• 2a-[4-(Tetrahydropyridoindol-2-yl)butyl]tetrahydrobenzindole Derivatives:  New Selective Antagonists of the 5-Hydroxytryptamine₇ Receptor
  作者：Chika Kikuchi、Takashi Ando、Takashi Watanabe、Hiroshi Nagaso、Masayo Okuno、Toyokazu Hiranuma、Masao Koyama

  DOI：10.1021/jm0104264

  日期：2002.5.1

  the 5-HT7 receptor, and the 9-carbamoyl moiety afforded increased selectivity. Compound 26j exhibited high affinity for the 5-HT7 receptor, with at least 280-fold selectivity over the 5-HT2 receptor. In a functional model of 5-HT7 receptor activation, this compound was confirmed to have 5-HT7 receptor antagonist activity. It should be a useful tool for clarifying the biological role of the 5-HT7 receptor

  制备了一系列四氢苯并吲哚，并评估了这些化合物对5-羟基色胺7（5-HT7）受体和其他受体的亲和力。大多数化合物对5-HT7受体显示出高亲和力，而2a- [4-（四氢吡啶并吲哚-2-基）丁基]四氢苯并吲哚衍生物（26a-j）对该受体具有高选择性。在四氢吡啶并吲哚环的9位上的取代基的性质影响了对5-HT7受体的亲和力，并且9-氨基甲酰基部分提供了增加的选择性。化合物26j显示出对5-HT7受体的高亲和力，其选择性是5-HT2受体的至少280倍。在5-HT7受体活化的功能模型中，证实该化合物具有5-HT7受体拮抗剂活性。
• [EN] NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES<br/>[FR] DERIVES AZOTES D'HOMO-CAMPTOTHECINE
  申请人：CALIFORNIA PACIFIC MED CENTER

  公开号：WO2003101998A1

  公开（公告）日：2003-12-11

  (20) esters of camptothecin analogs are provided. The compounds are (20) esters of an aminoalkanoic acid or an imidoalkanoic acid and homocamptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the homocamptothecin ring. The compounds are useful for treating cancer.

  提供了一种紧张素类似物的(20)酯。这些化合物是氨基烷酸或亚胺基烷酸与同伽蓝紧张素的(20)酯，该同伽蓝紧张素在7、9、10、11和12位置可能被取代。这些化合物可用于治疗癌症。
• Nitrogen-based camptothecin derivatives
  申请人：——

  公开号：US20030032624A1

  公开（公告）日：2003-02-13

  (20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of an aminoalkanoic acid or an imidoalkanoic acid and camptothecin, which is optionally substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The compounds are useful for treating cancer.

  提供了一种紫杉醇类似物的（20S）酯类。这些化合物是氨基烷基酸或亚胺基烷基酸和紫杉醇的（20S）酯，在紫杉醇环的第7、9、10、11和12位置可选择性地被取代。这些化合物可用于治疗癌症。